The proper course of action for treating lesions at bifurcations remains controversial. In the face of numerous small studies with conflicting results and in the absence of large-scale studies investigating whether--or how--to stent the side branch of a bifurcation, cardiologists are searching for solutions. It's all very confusing, but one thing is becoming increasingly clear. Drug-eluting stents, which work so well in straight segments of vessels, aren't working in bifurcated vessels because bifurcations are distinct segments of anatomy, with particular shapes and unique flow characteristics. Start-ups have picked up on the fact that there is a $1 billion interventional cardiology market just waiting to be served with the right technology, and almost a dozen young companies have crowded into the field.
By Mary Stuart
In interventional cardiology, it’s almost axiomatic that as new technology begins to successfully address one problem, it creates a new one. Not so long ago, it seemed that drug-eluting stents...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul
Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
The US FDA has given up on its effort to regulate lab-developed tests as medical devices, at least for now. The agency will not appeal a decision from the Eastern District of Texas that tossed out the FDA’s final rule, leaving the agency with few cards.
Abbott received the US FDA nod for its Tendyne system, offering a minimally invasive alternative to replace the valves of patients with severe mitral valve disease who are at risk for open-heart surgery.
SAGA Diagnostics has launched its breast cancer residual and recurrence detection test – Pathlight – in the US. The test’s ultrahigh sensitivity and specificity is rare to see in oncology, the company claimed.
